Here's a nomogram that gives the probability that SRT will work. I doubt that many men in their database had your specific high risk characteristics, so take it with a grain of salt. "Survival" is difficult to measure because the natural history of the disease is so long, and it is very expensive to track men in a clinical trial that long. Metastasis-free survival has proven to be a good surrogate endpoint (meaning it correlates well with overall survival), and biochemical recurrence-free survival is pretty good too, and is most often used.
riskcalc.org/ProstateCancerAfterRadicalProstatectomyNew/